References of "LANCELLOTTI, Patrizio"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailExtracorporeal CO2 removal and regional citrate anticoagulation in an experimental model of hypercapnic acidosis.
Morimont, Philippe ULiege; Habran, Simon; Desaive, Thomas ULiege et al

in Artificial Organs (2019)

Low flow extracorporeal veno-venous CO2 removal (ECCO2 R) therapy is used to remove CO2 while reducing ventilation intensity. However, the use of this technique is limited because efficiency of CO2 ... [more ▼]

Low flow extracorporeal veno-venous CO2 removal (ECCO2 R) therapy is used to remove CO2 while reducing ventilation intensity. However, the use of this technique is limited because efficiency of CO2 removal and potential beneficial effects on pulmonary hemodynamics are not precisely established. Moreover, this technique requires anticoagulation that may induce severe complications in critically ill patients. This study aimed at determining precisely efficiency of CO2 extraction and its effects on right ventricular (RV) afterload, and comparing regional anticoagulation with citrate to systemic heparin anticoagulation during ECCO2 R. ECCO2 R was highly efficient to normalize pH and PaCO2 and to reduce RV afterload resulting from hypercapnic acidosis. Regional anticoagulation with citrate solution was as effective as standard heparin anticoagulation but did not improve CO2 removal and lead to more hypocalcemia and hypotension. [less ▲]

Detailed reference viewed: 39 (6 ULiège)
Full Text
Peer Reviewed
See detailHER2+ breast cancer treatment and cardiotoxicity: monitoring and management.
Jerusalem, Guy ULiege; Lancellotti, Patrizio ULiege; Kim, Sung-Bae

in Breast cancer research and treatment (2019)

BACKGROUND: Breast cancer is a leading cause of death for women worldwide, with incidence increasing in lower-income countries. For patients with human epidermal growth factor receptor-2-positive (HER2 ... [more ▼]

BACKGROUND: Breast cancer is a leading cause of death for women worldwide, with incidence increasing in lower-income countries. For patients with human epidermal growth factor receptor-2-positive (HER2+) breast cancer, widespread availability of several agents targeting the HER2 receptor has resulted in survival gains over the past decades. However, improved survival has resulted in an increased need for management and mitigation of adverse events associated with anticancer therapy. Cardiac adverse events such as decreased ejection fraction and heart failure have been of particular concern in patients with HER2+ breast cancer. Anti-HER2 agents and chemotherapies (specifically anthracyclines, which are frequently used to treat HER2+ disease) have been associated with cardiotoxicity. As increasing numbers of patients are living longer due to more effective therapy, a better understanding of both monitoring and management of cardiotoxicity is urgently needed. METHODS: A comprehensive review of the literature was conducted via PubMed in January 2018 for phase II and phase III trials of "trastuzumab", "lapatinib", "pertuzumab", "T-DM1", "neratinib", in "breast cancer". Literature was evaluated for content related to cardiac adverse events. FINDINGS: We describe the incidence of and proposed mechanisms for the cardiotoxicity of available HER2-targeted therapies. We summarize current and emerging practices in the management of cardiotoxicity and provide guidance for routine patient care in real-world practice using illustrative patient scenarios. CONCLUSIONS: The future of cardiotoxicity management in patients with HER2+ breast cancer is discussed, with a focus on novel techniques to improve cardiac outcomes, including new imaging modalities, biomarkers, interventional therapies, and ongoing trials. [less ▲]

Detailed reference viewed: 19 (1 ULiège)
Full Text
Peer Reviewed
See detail2018 ESC/EACTS Guidelines on myocardial revascularization.
Sousa-Uva, Miguel; Neumann, Franz-Josef; Ahlsson, Anders et al

in European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery (2019), 55(1), 4-90

Detailed reference viewed: 15 (1 ULiège)
Full Text
Peer Reviewed
See detailEditorial: From Biology to Clinical Management: An Update on Aortic Valve Disease.
Oury, Cécile ULiege; Nchimi, Alain; Lancellotti, Patrizio ULiege

in Frontiers in Cardiovascular Medicine (2019), 6

Detailed reference viewed: 21 (2 ULiège)
Full Text
Peer Reviewed
See detailMaturation of heart valve cell populations during postnatal remodeling.
Hulin, Alexia ULiege; Hortells, Luis; Gomez-Stallons, M. Victoria et al

in Development (Cambridge, England) (2019), 146(12),

Heart valve cells mediate extracellular matrix (ECM) remodeling during postnatal valve leaflet stratification, but phenotypic and transcriptional diversity of valve cells in development is largely unknown ... [more ▼]

Heart valve cells mediate extracellular matrix (ECM) remodeling during postnatal valve leaflet stratification, but phenotypic and transcriptional diversity of valve cells in development is largely unknown. Single cell analysis of mouse heart valve cells was used to evaluate cell heterogeneity during postnatal ECM remodeling and leaflet morphogenesis. The transcriptomic analysis of single cells from postnatal day (P)7 and P30 murine aortic (AoV) and mitral (MV) heart valves uncovered distinct subsets of melanocytes, immune and endothelial cells present at P7 and P30. By contrast, interstitial cell populations are different from P7 to P30. P7 valve leaflets exhibit two distinct collagen- and glycosaminoglycan-expressing interstitial cell clusters, and prevalent ECM gene expression. At P30, four interstitial cell clusters are apparent with leaflet specificity and differential expression of complement factors, ECM proteins and osteogenic genes. This initial transcriptomic analysis of postnatal heart valves at single cell resolution demonstrates that subpopulations of endothelial and immune cells are relatively constant throughout postnatal development, but interstitial cell subpopulations undergo changes in gene expression and cellular functions in primordial and mature valves. [less ▲]

Detailed reference viewed: 24 (2 ULiège)
Full Text
Peer Reviewed
See detailValve Disease in Heart Failure: Secondary but Not Irrelevant.
Lancellotti, Patrizio ULiege; DULGHERU, Raluca Elena ULiege; MARCHETTA, Stella ULiege et al

in Heart Failure Clinics (2019), 15(2), 219-227

Secondary regurgitation caused by the remodeling and dysfunction of the left or right heart chamber may complicate heart failure, worsening both symptoms and prognosis. Outcome studies have shown that ... [more ▼]

Secondary regurgitation caused by the remodeling and dysfunction of the left or right heart chamber may complicate heart failure, worsening both symptoms and prognosis. Outcome studies have shown that patients' prognosis worsened as the severity of secondary regurgitation increases. Imaging and more specifically echocardiography plays a central role for diagnosis and serial assessment of secondary regurgitation as well as for timing the intervention and guiding the procedure. [less ▲]

Detailed reference viewed: 79 (4 ULiège)
Full Text
Peer Reviewed
See detailDrug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors.
Fogli, Stefano; Del Re, Marzia; Curigliano, Giuseppe et al

in Cancer Treatment Reviews (2019), 74

CDK4/6 inhibitors are a new class of anticancer drugs used for the treatment of women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer ... [more ▼]

CDK4/6 inhibitors are a new class of anticancer drugs used for the treatment of women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. Polypharmacy is a well-known problem in advanced cancer causing potential drug-drug interactions (DDIs), which, in turn, may limit the therapeutic value of CDK4/6 inhibitors. Therefore, understanding the mechanisms underlying potential DDIs in patients taking CDK4/6 inhibitors may be useful in decision-making processes and represent an important step towards treatment personalization. The present review is aimed at describing the potential DDIs that might occur in breast cancer patients receiving CDK4/6 inhibitors based on direct evidence from the literature and mechanistic considerations tailored on specific class of drugs used in combination. [less ▲]

Detailed reference viewed: 83 (2 ULiège)
Full Text
Peer Reviewed
See detailValue of Relative Myocardial Perfusion at MRI for Fractional Flow Reserve-Defined Ischemia: A Pilot Study.
Ghekiere, Olivier; Dacher, Jean-Nicolas; Dewilde, Willem et al

in AJR. American journal of roentgenology (2019)

OBJECTIVE: Correcting the perfusion in areas distal to coronary stenosis (risk) according to that of normal (remote) areas defines the relative myocardial perfusion index, which is similar to the ... [more ▼]

OBJECTIVE: Correcting the perfusion in areas distal to coronary stenosis (risk) according to that of normal (remote) areas defines the relative myocardial perfusion index, which is similar to the fractional flow reserve (FFR) concept. The aim of this study was to assess the value of relative myocardial perfusion by MRI in predicting lesion-specific inducible ischemia as defined by FFR. MATERIALS AND METHODS: Forty-six patients (33 men and 13 women; mean [+/- SD] age, 61 +/- 9 years) who underwent adenosine perfusion MRI and FFR measurement distal to 49 coronary artery stenoses during coronary angiography were retrospectively evaluated. Subendocardial time-enhancement maximal upslopes, normalized by the respective left ventricle cavity upslopes, were obtained in risk and remote subendocardium during adenosine and rest MRI perfusion and were correlated to the FFR values. RESULTS: The mean FFR value was 0.84 +/- 0.09 (range, 0.60-0.98) and was less than or equal to 0.80 in 31% of stenoses (n = 15). The relative subendocardial perfusion index (risk-to-remote upslopes) during hyperemia showed better correlations with the FFR value (r = 0.59) than the uncorrected risk perfusion parameters (i.e., both the upslope during hyperemia and the perfusion reserve index [stress-to-rest upslopes]; r = 0.27 and 0.29, respectively). A cutoff value of 0.84 of the relative subendocardial perfusion index had an ROC AUC of 0.88 to predict stenosis at an FFR of less than or equal to 0.80. CONCLUSION: Using adenosine perfusion MRI, the relative myocardial perfusion index enabled the best prediction of FFR-defined lesion-specific myocardial ischemia. This index could be used to noninvasively determine the need for revascularization of known coronary stenoses. [less ▲]

Detailed reference viewed: 40 (5 ULiège)
Peer Reviewed
See detailEARLY DETECTION OF CARDIAC DAMAGE
NOVO, G; NUGARA, C; LANCELLOTTI, Patrizio ULiege

in RUSSO, A; NOVO, G; LANCELLOTTI, Patrizio (Eds.) et al CARDIOVASCULAR COMPLICATIONS IN CANCER THERAPY (2019)

Detailed reference viewed: 22 (1 ULiège)
Peer Reviewed
See detailHEART FAILURE AND LEFT VENTRICULAR DYSFUNCTION
NOVO, G; NUGARA, C; LANCELLOTTI, Patrizio ULiege

in RUSSO, A; NOVO, G; LANCELLOTTI, Patrizio (Eds.) et al CARDIOVASCULAR COMPLICATIONS IN CANCER THERAPY (2019)

Detailed reference viewed: 24 (2 ULiège)
Peer Reviewed
See detailINTRODUCTION
RUSSO, A; NOVO, G; LANCELLOTTI, Patrizio ULiege et al

in RUSSO, A; NOVO, G; LANCELLOTTI, Patrizio (Eds.) et al Cardiovascular Complications in Cancer Therapy (2019)

Detailed reference viewed: 15 (0 ULiège)
See detailCardiovascular Complications in Cancer Therapy
RUSSO, A; NOVO, G; LANCELLOTTI, Patrizio ULiege et al

Book published by SPRINGER (2019)

Detailed reference viewed: 21 (2 ULiège)
Full Text
Peer Reviewed
See detailThe effect of surgical versus transcatheter aortic valve replacement on endothelial function. An observational study.
Moscarelli, Marco; Devito, Fiorella; Fattouch, Khalil et al

in International journal of surgery (London, England) (2019), 63

BACKGROUND: The effects of surgical aortic valve replacement versus transcatheter aortic valve replacement on endothelial function are unknown. We investigated the effects of surgical and transcatheter ... [more ▼]

BACKGROUND: The effects of surgical aortic valve replacement versus transcatheter aortic valve replacement on endothelial function are unknown. We investigated the effects of surgical and transcatheter aortic valve replacement on early and 90-day endothelial function measured by brachial flow mediated dilation and apoptotic rate in the human umbilical vein endothelial cells in patients with significant aortic stenosis, intermediate risk of surgery, and no coronary artery disease. METHODS: We conducted a prospective observational case control single-blind study at a single tertiary center. Endothelial function was measured at baseline, early post-procedure (4 days), and follow-up (90 days). A blood pressure cuff was used to elicit reactive hyperemia for measuring brachial wall shear stress and flow mediated dilation. The apoptosis rate was observed in the human umbilical vein endothelial cells after 48-h incubation with 20% serum from patients. The rate of apoptosis was assessed by determining the number of annexin V and propidium iodide positive cells by flow cytometry. RESULTS: Early post-procedure flow dilation was significant lower in the surgical group (p<0.003). At follow-up, both groups showed incremental increases in flow mediated dilation. Surgical group apoptotic rate did not significantly change, while transcatheter apoptotic rate steadily decreased, suggesting a trend toward improved endothelial function. CONCLUSIONS: The data suggest that conventional surgical aortic valve replacement may be associated with an early and transient decrease in endothelial function, likely due to the use of cardio-pulmonary bypass. [less ▲]

Detailed reference viewed: 41 (2 ULiège)
Full Text
Peer Reviewed
See detailImaging primary mitral regurgitation: the whole is better than the sum of its parts.
Lancellotti, Patrizio ULiege; Vannan, Mani A.

in European Heart Journal - Cardiovascular Imaging (2019)

Detailed reference viewed: 43 (2 ULiège)
Peer Reviewed
See detailP2X1 deficiency causes massive intestinal bleeding along with enhanced neutrophil-dependent thrombosis in colitis
Wéra, Odile ULiege; Servais, Laurence ULiege; Delierneux, Céline et al

Conference (2018, November)

Detailed reference viewed: 22 (9 ULiège)
Full Text
Peer Reviewed
See detailOutcomes of Patients With Asymptomatic Aortic Stenosis Followed Up in Heart Valve Clinics.
Lancellotti, Patrizio ULiege; Magne, Julien; DULGHERU, Raluca Elena ULiege et al

in JAMA Cardiology (2018)

Importance: The natural history and the management of patients with asymptomatic aortic stenosis (AS) have not been fully examined in the current era. Objective: To determine the clinical outcomes of ... [more ▼]

Importance: The natural history and the management of patients with asymptomatic aortic stenosis (AS) have not been fully examined in the current era. Objective: To determine the clinical outcomes of patients with asymptomatic AS using data from the Heart Valve Clinic International Database. Design, Setting, and Participants: This registry was assembled by merging data from prospectively gathered institutional databases from 10 heart valve clinics in Europe, Canada, and the United States. Asymptomatic patients with an aortic valve area of 1.5 cm2 or less and preserved left ventricular ejection fraction (LVEF) greater than 50% at entry were considered for the present analysis. Data were collected from January 2001 to December 2014, and data were analyzed from January 2017 to July 2018. Main Outcomes and Measures: Natural history, need for aortic valve replacement (AVR), and survival of asymptomatic patients with moderate or severe AS at entry followed up in a heart valve clinic. Indications for AVR were based on current guideline recommendations. Results: Of the 1375 patients included in this analysis, 834 (60.7%) were male, and the mean (SD) age was 71 (13) years. A total of 861 patients (62.6%) had severe AS (aortic valve area less than 1.0 cm2). The mean (SD) overall survival during medical management (mean [SD] follow up, 27 [24] months) was 93% (1%), 86% (2%), and 75% (4%) at 2, 4, and 8 years, respectively. A total of 104 patients (7.6%) died under observation, including 57 patients (54.8%) from cardiovascular causes. The crude rate of sudden death was 0.65% over the duration of the study. A total of 542 patients (39.4%) underwent AVR, including 388 patients (71.6%) with severe AS at study entry and 154 (28.4%) with moderate AS at entry who progressed to severe AS. Those with severe AS at entry who underwent AVR did so at a mean (SD) of 14.4 (16.6) months and a median of 8.7 months. The mean (SD) 2-year and 4-year AVR-free survival rates for asymptomatic patients with severe AS at baseline were 54% (2%) and 32% (3%), respectively. In those undergoing AVR, the 30-day postprocedural mortality was 0.9%. In patients with severe AS at entry, peak aortic jet velocity (greater than 5 m/s) and LVEF (less than 60%) were associated with all-cause and cardiovascular mortality without AVR; these factors were also associated with postprocedural mortality in those patients with severe AS at baseline who underwent AVR (surgical AVR in 310 patients; transcatheter AVR in 78 patients). Conclusions and Relevance: In patients with asymptomatic AS followed up in heart valve centers, the risk of sudden death is low, and rates of overall survival are similar to those reported from previous series. Patients with severe AS at baseline and peak aortic jet velocity of 5.0 m/s or greater or LVEF less than 60% have increased risks of all-cause and cardiovascular mortality even after AVR. The potential benefit of early intervention should be considered in these high-risk patients. [less ▲]

Detailed reference viewed: 108 (7 ULiège)
Full Text
Peer Reviewed
See detailAngioedema: a rare and sometimes delayed side effect of angiotensin-converting enzyme inhibitors.
DAVIN, Laurent ULiege; MARECHAL, Patrick ULiege; LANCELLOTTI, Patrizio ULiege et al

in Acta Cardiologica (2018)

The effects of angiotensin converting enzyme (ACE) inhibitors result from the inhibition of the ACE (kininase II) to ultimately influence both the renin-angiotensin system and the degradation of the ... [more ▼]

The effects of angiotensin converting enzyme (ACE) inhibitors result from the inhibition of the ACE (kininase II) to ultimately influence both the renin-angiotensin system and the degradation of the bradykinin (BK) metabolism. ACE inhibitors block the degradation of BK and substance P by ACE. In addition, an active metabolite of BK (Des-Arg9-BK) is catalysed by kininase I and its degradation is controlled in part by the conversion enzyme. These molecules have been associated with increased plasma extravasation associated with ACE inhibitors. ACE inhibitors are the leading cause of drug-induced Angioedema (AE). Symptoms of AE mainly occur after the first month of treatment by ACE. However, very late onset cases, sometimes after several years of stable therapy, are also described in the literature. It has been observed that patients previously stable under ACE inhibitor will most likely develop AE soon after the addition of another medication, including the combination of aspirin or non-steroid anti-inflammatory drugs with ACE inhibitor which has proved to be the most common cause, accounting for close to 50% of all AE cases related to ACE inhibitors. This side effect of ACE inhibitors, sometimes very late and rare, deserves to be recalled. [less ▲]

Detailed reference viewed: 152 (12 ULiège)